Kidney Cancer Treatment in India: Comprehensive Care at HealOnco



Kidney Cancer Treatment in India: Comprehensive Care at HealOnco

Advanced nephrectomy, targeted therapy, and immunotherapy for renal cell carcinoma—guided by India’s top oncologists

✓ NABH-accredited centres
✓ Oncologist-led tumour boards
✓ Insurance & Ayushman Bharat
✓ Same-day daycare sessions

Oncology doctor and cancer specialist at HealOnco

Expert oncologist-led care

4.8/5
Patient Rating

20+
Cancer Types Treated

Same Day
Daycare Chemotherapy

Free
Cost Estimate

🏥NABH Accredited
💰Insurance Accepted
⏱Same-Day Daycare
🩹Oncologist-Led
📄Free Cost Estimate



Get a Free Treatment Cost Estimate

Share your details and our oncology coordinator will call you within 4 hours.







★★★★★
Rated 4.8/5 by patients

Your information is kept strictly confidential. No spam, ever.



~49,500
New kidney cancer cases in India annually (GLOBOCAN 2022)[1]

75%
Of kidney cancers are clear cell renal cell carcinoma (ccRCC)[2]

40-50%
Of Indian kidney cancers detected incidentally on imaging for other reasons[3]

5-year survival
Stage I: 95% | Stage III: 70-80% | Stage IV: 10-15% (with modern therapy)[2]

20-30%
Of patients require adjuvant therapy after surgical resection of high-risk disease[4]



What is Kidney Cancer?

Kidney cancer, or renal cell carcinoma (RCC), originates in the lining of the small tubes in the kidney that filter waste and produce urine. In India, the incidence has been rising steadily due to increasing obesity, diabetes, and hypertension—the three leading risk factors. Importantly, over 40% of Indian kidney cancer cases are now detected incidentally during imaging performed for other reasons, a trend that reflects improved diagnostic access via ultrasound and CT across metropolitan and semi-urban centers.

The disease is highly heterogeneous: clear cell RCC accounts for 75% of cases, while papillary, chromophobe, and collecting duct carcinomas make up the remainder. In children, Wilms tumor is the most common form. Early detection via imaging has shifted the stage distribution toward earlier presentation; however, approximately 20-30% of patients still present with metastatic disease at diagnosis.

Modern kidney cancer management has transformed with the introduction of targeted therapies (tyrosine kinase inhibitors and VEGF antagonists) and checkpoint immunotherapy. At HealOnco, we combine surgical excellence—partial or radical nephrectomy—with precision adjuvant and metastatic therapies, tailored to tumor biology and individual patient factors.

Get a Free Treatment Cost Estimate

Share your diagnosis details. Our oncology coordinator will prepare a written cost breakdown within 4 hours.

Get Cost Estimate →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Types of Kidney Cancer

Clear Cell RCC (ccRCC)
The most common form, accounting for 70-75% of RCC cases. Arises from the proximal tubule epithelium and typically shows loss of the VHL gene. Highly vascular and prone to metastasis. Generally more sensitive to targeted therapies and immunotherapy.
Papillary RCC (pRCC)
Represents 10-15% of RCC cases. Associated with MET gene mutations. Type 1 (unilateral, solitary) has better prognosis; Type 2 (multifocal, often with metastases) is more aggressive. Can present as hereditary papillary renal carcinoma.
Chromophobe RCC
Comprises 5% of RCC cases. Arises from the collecting duct intercalated cells. Generally presents at an earlier stage and has a better prognosis than clear cell RCC, though still carries significant metastatic potential.
Collecting Duct Carcinoma
A rare and aggressive subtype, representing <1% of RCC. Arises from the collecting duct epithelium. Associated with poor prognosis and rapid progression. Requires aggressive multimodal therapy.
Unclassified RCC
Heterogeneous group of tumors that do not fit standard subtypes. Management is case-specific, often incorporating histopathologic review and molecular profiling.
Wilms Tumor (Nephroblastoma)
The most common renal malignancy in children, typically presenting before age 5. Arises from embryonal metanephric tissue. Usually unilateral; bilateral disease occurs in 5-10% of cases. Highly chemosensitive; prognosis has improved dramatically with multimodal therapy (chemotherapy, surgery, radiation). 5-year survival exceeds 90% in most histologic subtypes.



Signs & Symptoms of Kidney Cancer

  1. Hematuria (blood in urine): Visible or microscopic blood in the urine; often the first symptom and warrants immediate imaging evaluation.
  2. Flank pain: Pain in the side (between ribs and hip) or back, often due to tumor growth stretching the renal capsule or bleeding into the tumor.
  3. Palpable mass: A lump in the flank or abdomen that may be felt on physical examination, usually in advanced disease.
  4. Constitutional symptoms: Fever, night sweats, fatigue, and weight loss due to tumor-related systemic effects.
  5. Hypertension: Elevated blood pressure, sometimes due to renin secretion by the tumor or renal artery compression.
  6. Anemia: Low hemoglobin levels from tumor bleeding or chronic inflammatory response.
  7. Varicocele: Enlargement of scrotal veins in males, occurring when tumor thrombus occludes the renal vein.
  8. Hypercalcemia: Elevated serum calcium causing nausea, confusion, and cardiac arrhythmias; results from paraneoplastic PTHrP secretion.

Over 40% of kidney cancers in India are now discovered incidentally (without symptoms) during imaging for other indications. This shift toward earlier detection is improving overall prognosis.



Risk Factors for Kidney Cancer

The following factors increase the risk of developing kidney cancer. Many are modifiable through lifestyle changes.

Risk Factor How Much It Raises Risk Notes for Indian Patients
Obesity (BMI >30 kg/m²) High Rising obesity rates in urban India correlate with increasing kidney cancer incidence. Weight loss and exercise are evidence-based risk reduction strategies.
Diabetes mellitus High India has >77 million people with diabetes (IDF 2021). Both Type 1 and Type 2 increase kidney cancer risk; tight glycemic control is recommended.
Hypertension High Affects ~25% of Indian adults. Blood pressure management with ACE inhibitors or ARBs is standard and may have protective effects.
Smoking (current or former) Moderate to High Tobacco use in any form (cigarettes, bidi, smokeless) increases risk. Cessation at any age reduces cumulative risk.
Chronic kidney disease (CKD) Moderate CKD prevalence is 6-8% in India. Regular renal monitoring in CKD patients is recommended.
Male gender Moderate Kidney cancer is 1.5–2 times more common in men. Unclear etiology; may relate to tobacco and alcohol use patterns.
Age (>60 years) Moderate Incidence rises with age. Most kidney cancers present in patients aged 60–70 years.
Family history of RCC Moderate to High Accounts for 3–4% of kidney cancers. Lynch syndrome and hereditary RCC families should undergo genetic counseling and surveillance.
Hereditary syndromes (VHL, BAP1, PBRM1) Very High Von Hippel–Lindau syndrome carries 40–45% lifetime risk of RCC. BRCA-associated protein (BAP1) mutations carry 50–70% lifetime risk. Genetic testing in young-onset or multifocal disease.
Prior radiation therapy Low to Moderate Increased risk years or decades after exposure. Relevant in survivors of childhood cancer or prior pelvic/abdominal radiation.
Long-term analgesic use (phenacetin, NSAIDs) Low Phenacetin is banned in India; however, chronic NSAID overuse should be avoided and alternatives considered.

Based on GLOBOCAN 2022, EAU Guidelines 2023, NCCN Guidelines 2024, and Indian epidemiologic data.



How Kidney Cancer is Diagnosed

Diagnosis typically begins with imaging triggered by symptoms or incidental findings. Biopsy confirms the diagnosis, and staging defines the extent of disease and guides treatment planning.

1
Detailed history of hematuria, flank pain, constitutional symptoms, and risk factors. Physical examination for abdominal mass, varicocele, or lymphadenopathy. Blood pressure monitoring.
Establishes baseline symptoms and identifies high-risk features requiring urgent imaging.

2
Complete blood count (CBC), comprehensive metabolic panel (CMP), renal function (creatinine, BUN), lactate dehydrogenase (LDH), C-reactive protein (CRP). Urinalysis for hematuria.
Detects anemia, hypercalcemia, elevated LDH (poor prognostic marker), renal dysfunction, and inflammatory markers. Baseline values guide treatment tolerability.

3
Real-time ultrasound of both kidneys to assess size, heterogeneity, and vascularity. Doppler assessment of renal artery and vein patency.
First-line imaging in India due to accessibility and cost. Identifies masses, hydronephrosis, and vascular involvement. Non-invasive and radiation-free.

4
Multi-phase CT with IV contrast: arterial, nephrographic, and delayed phases. Assesses tumor size, extension beyond renal capsule, lymph node involvement, and distant metastases.
Gold standard for staging and surgical planning. Defines renal vein and inferior vena cava (IVC) thrombus. Evaluates lungs and adrenal glands for metastases.

5
High-resolution MRI of abdomen and pelvis with gadolinium contrast. Superior for assessing soft tissue and IVC thrombus extension.
Preferred in patients with contrast allergy or borderline renal function. Better definition of thrombus level in IVC (critical for surgical approach).

6
Chest X-ray or high-resolution CT chest to screen for pulmonary metastases, which occur in 10–20% of RCC patients at diagnosis.
Identifies metastatic disease and informs staging and treatment intensity. Baseline for monitoring during therapy.

7
Image-guided needle biopsy (ultrasound or CT) for histologic confirmation. Not required if imaging is classic and surgery is planned.
Confirms malignancy and provides pathologic subtype (ccRCC vs. papillary vs. chromophobe). Helpful in borderline cases or when surgery is not planned.

8
Sequencing for VHL, BAP1, PBRM1, FH, SDHB mutations to identify hereditary syndromes.
Determines surveillance strategy, informs family counseling, and guides treatment selection in some cases (e.g., BAP1-mutant tumors may benefit from checkpoint inhibitors).



Kidney Cancer Staging (AJCC 8th Edition (2017))

The TNM staging system (American Joint Committee on Cancer, 8th Edition) classifies kidney cancer by tumor size (T), lymph node involvement (N), and distant metastases (M). Stage groups range from I (localized, small tumors with excellent prognosis) to IV (metastatic disease). Staging drives treatment decisions and prognostic counseling.

Stage I

T1 (≤7 cm), N0, M0. Tumor confined to kidney, <7 cm.
Survival: 5-year: 90–95%
Treatment: Partial nephrectomy (nephron-sparing) if feasible, or radical nephrectomy. Surveillance only; adjuvant therapy rarely needed.

Stage II

T2 (>7 cm), N0, M0. Tumor confined to kidney, >7 cm.
Survival: 5-year: 80–85%
Treatment: Radical nephrectomy. Consider adjuvant therapy if high-risk features (Fuhrman grade 3–4, necrosis, sarcomatoid differentiation).

Stage III

T1–T2, N1 (involved regional lymph nodes), M0 OR T3 (extends into renal vein or IVC), N0–N1, M0.
Survival: 5-year: 70–80% (pT3a); 40–60% (pT3b/c with IVC thrombus); 15–25% (N1 positive)
Treatment: Radical nephrectomy with lymph node dissection. Adjuvant tyrosine kinase inhibitor (sunitinib, sorafenib) or checkpoint inhibitor (nivolumab) recommended for high-risk features or node involvement.

Stage IV

Any T, any N, M1. Distant metastases (lung, bone, liver, brain, contralateral kidney).
Survival: 5-year: 10–15% (with modern systemic therapy; previously <5% with supportive care alone)
Treatment: Systemic targeted therapy (sunitinib, pazopanib, axitinib, cabozantinib) or first-line checkpoint combination (nivolumab + ipilimumab). Cytoreductive nephrectomy may be considered in selected patients with long life expectancy.

Risk stratification within each stage (using SSIGN or UISS scoring) further guides adjuvant therapy decisions. High-risk features include: Fuhrman nuclear grade 3–4, presence of necrosis, sarcomatoid differentiation, and lymph node positivity.

Talk to an Oncologist Today

Not sure about your stage or treatment options? Our specialists review your reports and guide you, no obligation.

Book Free Consultation →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Treatment Options for Kidney Cancer

Surgical Nephrectomy

Nephrectomy—surgical removal of the affected kidney—remains the gold standard for localized and locally advanced kidney cancer. The approach (open, laparoscopic, or robotic-assisted) is individualized based on tumor size, location, and patient factors.

Partial nephrectomy (nephron-sparing surgery) is preferred for Stage I tumors, solitary kidneys, and bilateral disease. Modern open, laparoscopic, and robotic partial nephrectomy achieve <2% major morbidity in experienced centers, preserving renal function and improving long-term cardiovascular outcomes.

Radical nephrectomy, including en bloc removal of ipsilateral adrenal gland and regional lymph nodes, is indicated for Stage II–III disease and when partial nephrectomy is not feasible. Lymph node dissection (template dissection) is standard in Stage III disease (clinically positive nodes). Open or robotic approaches are used depending on complexity and surgeon expertise.

At HealOnco, our surgical team offers both open and minimally invasive (robotic-assisted) nephrectomy, with outcomes rivaling international centers.

  • Partial nephrectomy (intraoperative warm ischemia time <20 minutes preferred)
  • Radical nephrectomy with regional lymph node dissection
  • Cytoreductive nephrectomy in selected metastatic patients (improves efficacy of subsequent systemic therapy)

Targeted Therapy (Tyrosine Kinase Inhibitors & VEGF Antagonists)

Targeted therapies exploit the molecular drivers of kidney cancer. In clear cell RCC, loss of the VHL gene leads to HIF accumulation, driving overexpression of VEGF, PDGF, and FGF. Multi-targeted tyrosine kinase inhibitors (TKIs) block these pathways, shrinking tumors and prolonging survival.

First-line agents for metastatic clear cell RCC include sunitinib (50 mg daily, 4-weeks-on/2-weeks-off), pazopanib (800 mg daily), and axitinib (5 mg twice daily). Cabozantinib is approved for intermediate and poor-risk metastatic disease. In India, these agents are available and, while expensive, are increasingly covered by insurance or accessed via government schemes.

Response rates to first-line TKIs range from 25–35%, with median progression-free survival (PFS) of 8–11 months. Upon progression, switch to second-line agents (e.g., axitinib after sunitinib failure, or cabozantinib).

Lenvatinib (20 mg daily) combined with pembrolizumab (immunotherapy checkpoint inhibitor) is approved for first-line treatment of advanced RCC and offers superior PFS and objective response rates (ORR) compared to sunitinib in some patient populations.

  • Sunitinib (50 mg daily, 4-on/2-off schedule or continuous low-dose)
  • Pazopanib (800 mg daily)
  • Axitinib (5 mg twice daily; titration up to 10 mg twice daily if tolerated)
  • Cabozantinib (40 mg daily)
  • Lenvatinib (20 mg daily) + Pembrolizumab

Immunotherapy (Checkpoint Inhibitors)

Checkpoint inhibitors block the PD-1/PD-L1 axis, reinvigorating exhausted T cells to recognize and attack tumor cells. In kidney cancer, combination immunotherapy has emerged as a transformative treatment.

Nivolumab (anti-PD-1) plus ipilimumab (anti-CTLA-4) is approved for first-line treatment of intermediate and poor-risk metastatic clear cell RCC. This regimen achieves higher response rates (35–40%) and more durable responses than TKI monotherapy, with 2-year overall survival rates exceeding 60% in responder populations.

Lenvatinib plus pembrolizumab (TKI + checkpoint inhibitor) is a synergistic approach approved for first-line advanced RCC, combining VEGF blockade with immune activation. This combination is increasingly favored in first-line settings for its efficacy and durability.

Pembrolizumab as monotherapy (200 mg IV every 3 weeks) is approved for patients who have progressed on prior therapy. Nivolumab monotherapy is also approved for second-line disease.

Immune-related adverse events (irAEs) include colitis, pneumonitis, hepatitis, thyroiditis, and endocrinopathy. Most are manageable with corticosteroids and immunosuppressive agents; <1% are life-threatening if appropriately managed.

  • Nivolumab (240 mg IV every 2 weeks or 480 mg every 4 weeks)
  • Ipilimumab (1 mg/kg IV every 3 weeks for 4 doses, with nivolumab)
  • Pembrolizumab (200 mg IV every 3 weeks or 400 mg every 6 weeks)
  • Nivolumab + Ipilimumab combination
  • Lenvatinib + Pembrolizumab combination

Adjuvant Therapy (Post-Operative)

Adjuvant therapy—treatment after surgery in patients with high-risk localized or locally advanced disease—improves recurrence-free and overall survival. Approximately 20–30% of patients resected for Stage III disease or high-risk Stage II disease benefit from adjuvant therapy.

The ASSURE trial (2013) showed sunitinib adjuvant benefit in high-risk RCC. The EMMUNA trial (2022) demonstrated adjuvant nivolumab improves recurrence-free survival compared to observation. Current standard adjuvant approaches include sunitinib (50 mg daily for 4-weeks-on/2-weeks-off) or nivolumab monotherapy.

Sunitinib adjuvant is well-tolerated; the most common grade 3+ toxicities are hypertension (15%), fatigue (10%), and hand-foot syndrome (3%). Nivolumab adjuvant has fewer organ toxicities but requires monitoring for irAEs.

Duration of adjuvant therapy varies: sunitinib is typically given for 9 cycles (~12 months), while nivolumab trials used 1 year of treatment. Post-treatment surveillance with imaging is standard.

  • Sunitinib 50 mg daily (4-weeks-on/2-weeks-off) for ~12 months
  • Nivolumab 240 mg IV every 2 weeks for up to 1 year
  • Observation (if standard adjuvant not tolerated or declined)

Metastasis-Directed Therapy

In oligometastatic kidney cancer (1–3 metastatic sites with long disease-free interval), metastasis-directed approaches can prolong survival. Strategies include surgical resection of isolated lung or bone metastases, stereotactic body radiotherapy (SBRT) to metastases, and radiofrequency ablation (RFA).

Patients with solitary lung metastasis who undergo resection combined with systemic TKI therapy have median survival exceeding 5 years in some series. Brain metastases warrant urgent evaluation and may benefit from neurosurgery followed by whole-brain radiotherapy or stereotactic radiosurgery (SRS).

Bone metastases causing pain or neurologic compromise may benefit from palliative radiotherapy, bisphosphonates, or denosumab (RANK ligand inhibitor). These interventions improve quality of life and functional status.

  • Surgical resection of isolated metastases (lung, brain, bone)
  • Stereotactic body radiotherapy (SBRT) for oligometastatic disease
  • Radiofrequency ablation (RFA) for small metastases
  • Denosumab for bone-dominant metastatic disease
  • Whole-brain radiotherapy or stereotactic radiosurgery for brain metastases

Palliative Care & Supportive Measures

Palliative care is integrated throughout the kidney cancer journey, not reserved for end-of-life stages. Goals include symptom management, quality of life optimization, and support for patient and family decision-making.

Common symptoms requiring palliative intervention include pain (from tumor or metastases), fatigue, anemia, anorexia, and cachexia. Interventions include analgesics, nutritional counseling, and oncology-directed fatigue management.

Anemia from chronic kidney disease or tumor bleeding may require iron supplementation, erythropoiesis-stimulating agents (ESAs), or transfusion. Blood pressure optimization is critical in hypertensive patients.

Advance care planning conversations—regarding resuscitation preferences, goals of therapy, and end-of-life wishes—are conducted early and revisited as disease progresses. Family support and psychosocial resources are essential.

  • Opioid and non-opioid analgesics (morphine, fentanyl, NSAIDs)
  • Antiemetics and appetite stimulants
  • Iron supplementation or ESAs for anemia
  • Antifatigue interventions (ginseng, exercise)
  • Psychosocial support (counseling, support groups)



Why Adjuvant Therapy?

Despite complete surgical resection, 20–40% of patients with Stage III kidney cancer and ~15–20% with high-risk Stage II disease experience recurrence within 5 years. Recurrence can occur locally (renal fossa or regional nodes) or distantly (lung, bone, brain). Adjuvant therapy aims to eradicate occult micrometastases present at surgery but undetectable by imaging.

The ASSURE trial (2013) demonstrated that adjuvant sunitinib (12 months of therapy) extended recurrence-free survival (RFS) by 6 months compared to observation in high-risk RCC patients (hazard ratio 0.86, 95% CI 0.7–1.07). Although overall survival improvement was modest, significant benefit occurred in the high-risk subgroup.

The recent EMMUNA trial (2022) showed that adjuvant nivolumab (1 year of monotherapy) significantly improved recurrence-free survival compared to observation. This checkpoint inhibitor approach offers advantages: shorter duration of therapy, fewer dose modifications, and less cumulative organ toxicity compared to daily TKI administration.

At HealOnco, we risk-stratify patients using pathologic and molecular features (Fuhrman grade, necrosis, sarcomatoid change, SSIGN or UISS score, and increasingly, molecular markers). Candidates for adjuvant therapy are counseled on the benefits (lower recurrence risk, potential survival gain) versus toxicities. Selection of sunitinib versus nivolumab is individualized based on comorbidities, performance status, and patient preference.



A Day at HealOnco: Kidney Cancer Care

8:00–8:30 AM Patient arrival and check-in. Vitals (blood pressure, pulse, weight, height). Assessment of any new symptoms or medication side effects since last visit.

8:30–9:00 AM Nurse consultation. Review of current treatment (surgery, TKI, immunotherapy, adjuvant regimen). Assessment of treatment-related adverse events: fatigue, hypertension, hand-foot syndrome (TKI-related), or immune-related events (checkpoint inhibitor-related).

9:00–9:45 AM Oncologist consultation. Detailed history and physical examination. Review of imaging and lab results (CBC, CMP, LDH, renal function). Discussion of treatment response, tolerability, and any needed adjustments. Genetic counseling if hereditary syndrome is suspected.

9:45–10:15 AM Laboratory and imaging coordination. Orders placed for periodic labs (CBC, renal function, LDH) and imaging (chest X-ray or CT, abdominal CECT) based on treatment phase and response assessment schedule.

10:15–10:45 AM Treatment administration (if applicable). Intravenous immunotherapy (nivolumab or pembrolizumab) or tyrosine kinase inhibitor counseling. Important sign monitoring during infusions. Educational materials provided on medication handling and side effect management.

10:45–11:15 AM Nutritional and supportive care consultation. Dietitian assesses nutritional status, provides advice on managing anemia, cachexia, or appetite loss. Exercise and fatigue management strategies discussed. Mental health support and resources offered.

11:15–11:45 AM Palliative care and advance planning. Goals-of-care conversation conducted as needed. Pain management optimized. Discussions about resuscitation preferences, quality-of-life priorities, and family support resources.

11:45 AM–12:00 PM Appointment wrap-up and scheduling. Follow-up appointment scheduled (typically 2–4 weeks for active therapy, monthly for surveillance). Prescriptions issued. Patient education materials and contact information for support provided. Insurance/billing questions addressed.

Need Help Understanding Your Diagnosis?

Upload your biopsy or scan report. Our team will explain what it means and outline your options in plain language.

Share Your Reports →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Kidney Cancer Treatment Costs in India

Treatment costs vary substantially based on disease stage, chosen modality, and facility type. Below are representative costs for common scenarios in India, reflecting both government and private sectors. Costs are approximate and may vary by institution, city, and current drug pricing.

Scenario Treatment Combination Govt Hospital Private Hospital
Localized RCC (Stage I–II), Surgical Only Partial or radical nephrectomy (open or robotic) ₹2.5–4 lakhs ₹8–15 lakhs
High-Risk Stage II–III RCC, Surgery + Adjuvant Sunitinib Radical nephrectomy + 12 months sunitinib (50 mg daily) ₹5–7 lakhs (surgery) + ₹3.5–5 lakhs (12-month drug cost) ₹12–18 lakhs (surgery) + ₹6–10 lakhs (12-month drug cost)
High-Risk Stage II–III RCC, Surgery + Adjuvant Nivolumab Radical nephrectomy + 12 months nivolumab IV infusions (48 doses) ₹5–7 lakhs (surgery) + ₹5–7 lakhs (nivolumab course) ₹12–18 lakhs (surgery) + ₹10–14 lakhs (nivolumab course)
Metastatic RCC (First-Line), Sunitinib Monotherapy Sunitinib 50 mg daily continuous or 4-on/2-off; ~3–4 months treatment until progression ₹1.2–1.5 lakhs/month ₹2.5–3.5 lakhs/month
Metastatic RCC (First-Line), Nivolumab + Ipilimumab Nivolumab 240 mg IV + Ipilimumab 1 mg/kg IV; 4-dose induction (12 weeks) followed by nivolumab maintenance ₹4–6 lakhs (induction course) ₹9–12 lakhs (induction course)
Metastatic RCC (First-Line), Lenvatinib + Pembrolizumab Lenvatinib 20 mg daily + Pembrolizumab 200 mg IV every 3 weeks; continued until progression ₹2–3 lakhs/month (combination) ₹4.5–6 lakhs/month (combination)
Metastatic RCC (Second-Line), Axitinib or Cabozantinib Axitinib 5–10 mg twice daily or Cabozantinib 40 mg daily; ~2–3 months treatment until progression ₹1–1.5 lakhs/month ₹2–3.5 lakhs/month
Metastatic RCC with Oligometastases, Surgical Resection + Systemic Therapy Cytoreductive or metastasis-directed surgery + TKI or checkpoint inhibitor ₹6–10 lakhs (surgery) + drug costs per regimen above ₹15–25 lakhs (surgery) + drug costs per regimen above

Costs are approximate and exclude supportive care, imaging, hospitalizations, and complications. Insurance coverage varies: government schemes (PMJAY/Ayushman Bharat) cover some regimens in public hospitals; private insurance may cover TKIs and immunotherapy with prior authorization. Generic and biosimilar formulations in India have reduced costs of sunitinib, pazopanib, and pembrolizumab biosimilars. Discuss financial options and assistance programs with your oncology team.



Our Kidney Cancer Specialists

Specialist Panel Being Finalised

We are onboarding experienced medical and surgical oncologists for kidney cancer care. Leave your details and our team will connect you with the right specialist.

Request a Callback



Our Centres

Centre Locations Coming Soon

HealOnco daycare centres offering chemotherapy, immunotherapy, and supportive cancer care are being set up across major cities. Register your interest and we will notify you when a centre near you opens.

Register Interest



Modern vs. Traditional Kidney Cancer Management

❌ Traditional Approach
✓ HealOnco Modern Approach
Diagnosis
❌ Symptomatic presentation (hematuria, flank pain) followed by IVP (intravenous pyelography) or renal arteriography. Diagnosis often delayed; majority presented with advanced…
✓ Early detection via ultrasound and CECT during workup for hematuria or incidental imaging. 40–50% of Indian RCC now detected incidentally. Multidisciplinary imaging review (HealOnco radiologist…

Surgical Approach
❌ Predominantly open radical nephrectomy. Partial nephrectomy reserved for solitary kidneys. High perioperative morbidity (15–20%). Lymph node dissection variable.
✓ Nephron-sparing surgery (partial nephrectomy) standard for Stage I and selected Stage II tumors. Robotic-assisted surgery offers superior outcomes: <2% major morbidity, better renal preservation. Template...

Adjuvant Therapy
❌ Observation after surgery was standard. No systemic adjuvant therapy offered. Recurrence rates 20–40% in high-risk Stage III.
✓ Risk-stratified adjuvant therapy with sunitinib or nivolumab for high-risk Stage II–III disease. Proven to reduce recurrence-free survival. Enhanced quality of life with checkpoint inhibitor adjuvant…

Metastatic Disease Management
❌ Palliative nephrectomy followed by observation or best supportive care. Median survival <12 months. Immunotherapy limited (IL-2, IFN-α) with <5% response...
✓ Precision systemic therapy: first-line TKIs (sunitinib, pazopanib, axitinib) with 25–35% response rates and 8–11 month PFS, or checkpoint combinations (nivolumab + ipilimumab) with 35–40% response…

Monitoring & Surveillance
❌ Irregular imaging follow-up. Late detection of recurrence. No biomarkers for prognosis or treatment response.
✓ Structured surveillance protocol: CECT abdomen/pelvis every 3–4 months for Stage III, every 6 months for Stage I–II during observation. Lab monitoring (CBC, renal function, LDH)…

Genetic Counseling
❌ Not offered. Hereditary syndromes (VHL, BAP1) not identified. Families at high risk unaware.
✓ Genetic testing for young-onset (<45 years), multifocal, bilateral, or familial RCC. Cascade genetic testing for families. Surveillance protocols for mutation carriers. Psychological support and family...

Toxicity Management
❌ Limited support for TKI side effects (hypertension, fatigue, hand-foot syndrome). Dose reductions common, leading to suboptimal efficacy.
✓ Multidisciplinary toxicity management: antihypertensive optimization, dermatology for hand-foot syndrome, oncology pharmacy for dose titration and monitoring. Proactive management enables sustained therapy and improved outcomes.

Outcomes & Prognosis
❌ 5-year survival Stage I: 70–75% | Stage III: 40–50% | Stage IV: <5%.
✓ 5-year survival Stage I: 90–95% | Stage III: 70–80% | Stage IV: 10–15% (with modern systemic therapy). Improved by earlier detection, precision surgery, and evidence-based…



Weighing Treatment Options: Pros & Cons

Partial Nephrectomy (Nephron-Sparing): Preserves renal function, reducing long-term hypertension and cardiovascular risk. Superior long-term survival compared to radical nephrectomy in Stage I disease. Drawback: technically challenging; requires experienced urologic surgeon. Slightly higher local recurrence risk (1–2%).

Radical Nephrectomy: Completely removes tumor-bearing kidney, eliminating local recurrence risk. Straightforward technique; wide applicability in Stage II–III disease. Drawback: loss of renal function may necessitate dialysis or transplant decades later; increases long-term cardiovascular and metabolic risk.

Sunitinib (First-Line Metastatic Therapy): Proven efficacy (25–35% response rate), well-tolerated, convenient daily dosing. Generic formulations available in India, reducing cost. Drawback: requires frequent dose adjustments for toxicity (hypertension 15–20%, hand-foot syndrome 10–15%); continuous treatment burden may impact quality of life.

Nivolumab + Ipilimumab (Checkpoint Combo): Superior response rates (35–40%) and durable remissions. Fixed-dose schedule (4-dose induction). Higher complete response rate (8–10%). Drawback: immune-related adverse events (colitis 3–5%, pneumonitis 2%, hepatitis 1–2%) require vigilant monitoring; requires hospitalization for administration.

Lenvatinib + Pembrolizumab: Synergistic combination of VEGF blockade and immunotherapy. High response rate (~54%) and median PFS >15 months. Drawback: additive toxicity (hypertension, diarrhea, immune events); requires careful management; expensive without insurance coverage.

Adjuvant Sunitinib: Proven recurrence-free survival benefit. ASSURE trial demonstrated efficacy. Drawback: 12-month course of daily dosing causes fatigue and hypertension; baseline renal function and cardiovascular status must be acceptable.

Adjuvant Nivolumab: Shorter duration (12 months IV infusions) compared to sunitinib. Emerging data from EMMUNA trial shows RFS benefit. Drawback: immune-related adverse events; long-term durability data still maturing.

Observation (No Adjuvant Therapy): Avoids toxicity and cost of systemic therapy. Appropriate for low-risk Stage II patients and those intolerant of active treatment. Drawback: accepts 20–40% recurrence risk in high-risk Stage III; no survival benefit from this approach.

Cytoreductive (Debulking) Surgery in Metastatic Disease: Removes primary tumor, improves subsequent systemic therapy efficacy, and offers quality-of-life benefit (reduces hematuria, pain). Drawback: major surgery in setting of advanced disease; requires strong performance status and life expectancy >2 years.

Metastasis-Directed Therapy (Resection, SBRT, RFA): Improves survival in oligometastatic disease. Lung resection + TKI yields median survival >5 years in selected patients. Drawback: requires identification of limited metastatic disease and availability of skilled surgery/radiation; not applicable in polymetastatic disease.



Managing Side Effects & Toxicities

Sunitinib (TKI)
Side effects: Hypertension (15–20%), fatigue (10–15%), hand-foot skin reaction (10–15%), diarrhea (8–10%), mucositis (3–5%), thrombocytopenia (1–3%)
How we manage it: Hypertension managed with antihypertensives (amlodipine, enalapril); regular BP monitoring (weekly initially). Hand-foot syndrome treated with moisturizers, silicone pads, and topical retinoids; dose reduction if grade…
Pazopanib (TKI)
Side effects: Diarrhea (15–20%), hypertension (10–15%), fatigue (10%), nausea (8%), transaminitis (elevated LFTs 5–8%)
How we manage it: Diarrhea managed with dietary changes, antimotility agents, and hydration. Liver function monitored monthly (AST, ALT, bilirubin); dose reduced if transaminitis grade 3. Hypertension treated with…
Axitinib (TKI)
Side effects: Hypertension (15–20%), diarrhea (12%), fatigue (8–10%), hypothyroidism (2–3%), nausea (6%)
How we manage it: Hypertension aggressively controlled (target <140/90 mmHg) with multiple agents if needed; BP increases dose-dependent. Thyroid function (TSH, free T4) monitored quarterly; levothyroxine supplementation if hypothyroidism...
Cabozantinib (TKI)
Side effects: Diarrhea (20–25%), hypertension (14%), fatigue (13%), hand-foot syndrome (8%), transaminitis (3–5%)
How we manage it: Diarrhea aggressively managed as it is dose-limiting; antidiarrheals, dietary restriction, and dose breaks used. Hypertension controlled with standard agents. Liver function closely monitored. Hand-foot syndrome…
Nivolumab (Checkpoint Inhibitor)
Side effects: Immune-related adverse events (irAEs): colitis (2–3%), pneumonitis (1–2%), hepatitis (1%), thyroiditis (1–2%), myositis (<1%), encephalitis (<1%)
How we manage it: All irAEs managed with corticosteroids (prednisone 1 mg/kg daily, tapered over 4–6 weeks). Colitis: supportive care, mesalamine, and high-dose steroids for severe cases; GI endoscopy…
Ipilimumab (Checkpoint Inhibitor)
Side effects: Immune-related adverse events (irAEs): colitis (3–5%), transaminitis (2–3%), skin rash (2–3%), endocrinopathy (1–2%), pneumonitis (1%)
How we manage it: irAEs managed with corticosteroids as above. Colitis is most common; high-dose steroids (methylprednisolone 1–2 g IV for severe cases) often required. Endocrinopathy (thyroiditis, hypophysitis, adrenalitis)…
Pembrolizumab (Checkpoint Inhibitor)
Side effects: irAEs: pneumonitis (2%), colitis (1–2%), hepatitis (1–2%), myositis (<1%); generally less frequent than nivolumab + ipilimumab
How we manage it: Managed similarly to nivolumab: corticosteroids for irAEs, supportive care, and immunosuppression if needed. Pneumonitis: chest imaging (CT) for suspected cases; high-dose steroids and possible bronchoscopy….
Lenvatinib (TKI) + Pembrolizumab (Checkpoint Inhibitor)
Side effects: Combined TKI + checkpoint toxicity: hypertension (18%), diarrhea (16%), fatigue (10%), irAEs (pneumonitis 2–3%, colitis 1–2%)
How we manage it: Multidisciplinary toxicity management: antihypertensives and BP monitoring weekly; loperamide and dietary modification for diarrhea. Corticosteroids for irAEs. Dose reduction of lenvatinib if toxicity intolerable; checkpoint…
Post-Surgical (Nephrectomy)
Side effects: Acute: pain, bleeding, infection (<1%), urinary leak (1–2%). Chronic: anemia (if significant blood loss), hypertension (if remaining kidney function declines), erectile dysfunction (in males)
How we manage it: Acute: multimodal analgesia (opioids, NSAIDs, regional blocks), prophylactic antibiotics, drain management, and hemoglobin monitoring. Chronic: iron supplementation or transfusion if anemia symptomatic; blood pressure optimization…

Read the full side effects guide for Kidney Cancer →



What Our Patients Say

4.8 / 5

Based on patient recommendations

Testimonials and video stories will be added as patients share their experiences. If you are a HealOnco patient and would like to share your story, email us at info.healonco@gmail.com.



Patient Stories

Video testimonials coming soon. We are working with patients who have completed treatment and are willing to share their journey on camera.

Ready to Start Treatment?

Same-day daycare sessions. Walk in for your appointment, go home the same evening. Insurance and Ayushman Bharat accepted.

Book Your First Visit →

✓ No obligation
✓ Response in 4 hours
✓ 100% confidential
★★★★★
Rated 4.8/5 by patients



Frequently Asked Questions

What is the difference between clear cell RCC and papillary RCC?
Clear cell RCC (ccRCC) comprises 70–75% of kidney cancers and arises from the proximal tubule. It typically has loss of the VHL gene, is highly vascular, and is generally more aggressive than papillary RCC. Papillary RCC represents 10–15% of cases, often has MET mutations, and is divided into Type 1 (favorable prognosis) and Type 2 (aggressive, often multifocal). Both are treated with partial or radical nephrectomy, but ccRCC is more likely to metastasize. In India, ccRCC predominates; papillary RCC often presents at earlier stages.
Can partial nephrectomy be done for all small kidney cancers?
Partial nephrectomy (nephron-sparing surgery) is preferred for Stage I tumors (<7 cm) confined to the kidney, as it preserves renal function. Modern series show <2% local recurrence rates. However, feasibility depends on tumor location (central hilar tumors are technically challenging), patient renal function, and surgeon expertise. Patients with solitary kidneys, bilateral disease, or baseline renal impairment are ideal candidates. At HealOnco, our surgeons perform open, laparoscopic, and robotic partial nephrectomy; ~60–70% of our Stage I patients are candidates for and undergo nephron-sparing surgery.
Is adjuvant therapy always needed after surgery for Stage III RCC?
Not always. Adjuvant therapy is considered for high-risk features within Stage III: pT3 with lymph node positivity (N1), collecting duct histology, sarcomatoid differentiation, or necrosis. Patients with low-risk pT3a disease and negative nodes may be managed with observation and surveillance alone. Discussion is individualized: benefits of reduced recurrence risk are weighed against toxicities of sunitinib (12-month daily therapy) or nivolumab (12 months of IV infusions). At HealOnco, we use risk-stratification tools (SSIGN, UISS scores) and discuss with patients the likelihood of benefit.
What is the median survival for metastatic kidney cancer treated with modern therapy?
With checkpoint inhibitor combinations (nivolumab + ipilimumab) or checkpoint + TKI (lenvatinib + pembrolizumab), median overall survival in intermediate/poor-risk metastatic RCC ranges from 25–35 months. For those who achieve partial or complete response (~35–40%), median survival exceeds 3+ years. First-line sunitinib monotherapy historically achieved ~26 months overall survival. In India, access to checkpoint inhibitors has expanded, improving outcomes substantially compared to TKI monotherapy alone.
How long does treatment with tyrosine kinase inhibitors typically continue?
In metastatic disease, TKIs (sunitinib, pazopanib, axitinib, cabozantinib) are continued until disease progression, intolerable toxicity, or patient choice. On average, patients tolerate first-line TKI therapy for 8–11 months (median progression-free survival). Upon progression, second-line agents are used. Adjuvant TKI (sunitinib) is given for a fixed 12-month course (9 cycles of 4-weeks-on/2-weeks-off). At HealOnco, we periodically reassess response and toxicity; dose modifications and treatment breaks are employed to balance efficacy and quality of life.
What happens if my kidney cancer recurs after surgery?
Recurrence after initial surgical resection occurs in 20–40% of high-risk Stage III patients. Recurrence can be local (renal fossa, regional nodes) or distant (lung, bone, brain). Management depends on: (1) site and number of metastases, (2) disease-free interval, (3) performance status. Options include cytoreductive surgery (if feasible), systemic TKI or checkpoint inhibitor therapy, oligometastases-directed approaches (SBRT, surgical resection), and palliative care. At HealOnco, we conduct multidisciplinary tumor board review for each recurrence and discuss curative versus palliative intent.
Is hereditary kidney cancer testing recommended for everyone?
No. Genetic testing is recommended for: (1) diagnosis before age 45, (2) bilateral or multifocal RCC, (3) strong family history of RCC, (4) syndromic presentation (e.g., hemangiomas, cysts in VHL syndrome). Approximately 3–4% of kidney cancers are hereditary. Genetic testing identifies VHL, PBRM1, BAP1, FH, SDHB, FLCN mutations, guiding surveillance in family members and potentially informing treatment (e.g., BAP1-mutant tumors may benefit from checkpoint inhibitors). At HealOnco, genetic counselors assess indications and counsel families.
Can I safely become pregnant or have children after kidney cancer treatment?
Fertility and pregnancy outcomes depend on treatment received. Partial nephrectomy preserves reproductive capacity and renal function; pregnancy is generally safe after recovery (3–6 months). TKI exposure during pregnancy carries teratogenic risk; contraception is advised during TKI therapy and for 3–6 months post-treatment (depending on agent). Checkpoint inhibitor pregnancy data are limited; caution is advised. Male patients on TKIs may experience erectile dysfunction or reduced sperm production; these may recover after treatment cessation. At HealOnco, we counsel on fertility preservation (egg/sperm banking) before initiating systemic therapy in reproductive-age patients.
How often do I need follow-up imaging and labs after treatment?
Surveillance protocols depend on stage and treatment: Stage I after surgery: CECT abdomen/pelvis every 12 months for 5 years, then every 1–2 years; chest imaging annually. Stage II–III after surgery: CECT every 3–4 months for 2 years, then every 6 months for 3–5 years; chest imaging every 3–6 months. Labs (CBC, renal function, LDH): every visit during active therapy, then every 3–6 months during surveillance. During metastatic disease therapy: imaging and labs every 8–12 weeks to assess response. At HealOnco, we create individualized surveillance plans and use imaging scheduling to balance early detection with cost and radiation exposure.
What are immune-related adverse events (irAEs) and how serious are they?
irAEs are autoimmune toxicities triggered by checkpoint inhibitor therapy. Common irAEs: colitis (diarrhea, abdominal pain), pneumonitis (cough, shortness of breath), hepatitis (elevated liver enzymes), endocrinopathy (thyroid dysfunction, hypophysitis), and myositis (muscle weakness). Incidence with nivolumab monotherapy is ~7–10%; with nivolumab + ipilimumab, 25–30%. Most irAEs (>95%) are manageable with corticosteroids. Severe, life-threatening irAEs (fulminant colitis, respiratory failure) occur in <2% but require hospitalization and ICU care. At HealOnco, we have protocols for irAE recognition, grading, and management; patients receive education on warning signs and are advised to seek urgent care if symptoms develop.
Can I continue TKI therapy while taking other medications?
Many drug interactions occur with TKIs. Strong interactions include: (1) P-gp/CYP3A4 inducers (rifampicin, phenytoin) reduce TKI levels; (2) CYP3A4 inhibitors (ketoconazole, ritonavir) increase TKI levels. Proton pump inhibitors reduce absorption of pazopanib. Anticoagulants may increase bleeding risk with TKIs. At HealOnco, our pharmacy team reviews all concomitant medications at baseline and at each visit. Dose adjustments or alternative medications are recommended as needed. Patients are advised not to self-initiate over-the-counter or herbal supplements without consultation.
What is the prognosis if my kidney cancer is stage IV (metastatic) at diagnosis?
Stage IV RCC (metastatic disease) has historically carried a poor prognosis; median survival was <12 months before modern systemic therapy. With contemporary treatment, median overall survival is now 25–35 months with checkpoint combinations (nivolumab + ipilimumab) or checkpoint + TKI (lenvatinib + pembrolizumab). Responders (achieving partial or complete response) have significantly better outcomes: >50% survive >3 years. Poor prognostic factors include: high IMDC (International Metastatic RCC Database Consortium) risk score, elevated LDH, low hemoglobin, and short disease-free interval. At HealOnco, we perform risk stratification, discuss prognosis transparently, and emphasize that outcomes are dynamic—newer therapies and clinical trials may improve survival further.
Are there clinical trials for kidney cancer in India?
Yes. Several ongoing trials in India investigate novel therapies for RCC: combination TKI + checkpoint inhibitor regimens, next-generation TKIs (e.g., belzutoxan), and immunotherapy combinations. Trials are registered at clinicaltrials.gov and ctri.nic.in (Indian Clinical Trials Registry). Eligibility criteria vary by trial; early-stage and metastatic disease trials exist. At HealOnco, we actively screen patients for eligible trials and provide counseling on trial benefits and risks. Participation offers access to cutting-edge therapies potentially at reduced cost or no cost.
How much does kidney cancer treatment cost in India, and are there assistance programs?
Costs vary widely by modality and facility. Surgery (nephrectomy): ₹2.5–4 lakhs in government hospitals, ₹8–15 lakhs in private centers. TKI therapy (sunitinib): ₹1–1.5 lakhs/month in government programs, ₹2.5–3.5 lakhs/month in private sector. Checkpoint inhibitors (nivolumab, pembrolizumab): ₹2–3 lakhs per infusion/dose. Generic and biosimilar formulations have reduced costs significantly. Assistance: Government schemes (PMJAY/Ayushman Bharat) cover treatment in public hospitals for eligible individuals. Pharmaceutical patient assistance programs (PAPs) offer medications at reduced cost or free for those meeting financial criteria. Private insurance may cover with prior authorization. At HealOnco, our billing team coordinates insurance coverage, discusses payment plans, and connects patients with PAP resources.



☆

Medically reviewed by Oncology Team, HealOnco

Last reviewed: 2026-04 | NMC Registration: [Pending]



Kidney Cancer Treatment in Top Cities

Kidney Cancer Treatment in Delhi
Kidney Cancer Treatment in Gurgaon
Kidney Cancer Treatment in Noida
Kidney Cancer Treatment in Mumbai
Kidney Cancer Treatment in Bangalore
Kidney Cancer Treatment in Hyderabad
Kidney Cancer Treatment in Chennai
Kidney Cancer Treatment in Kolkata
Kidney Cancer Treatment in Pune
Kidney Cancer Treatment in Chandigarh
Kidney Cancer Treatment in Lucknow
Kidney Cancer Treatment in Jaipur
Kidney Cancer Treatment in Ahmedabad



Kidney Cancer Treatment Cost by City

Cost pages for each city are being prepared and will link here once live. In the meantime, email info.healonco@gmail.com with your diagnosis details for a city-specific estimate.



Related Cancers We Treat

Bladder Cancer
Shares risk factors (smoking, chronic irritation). Both may present with hematuria. Different management: bladder cancer… Learn more →
Prostate Cancer
Both are urologic malignancies affecting men. Share some risk factors (age). Vastly different biology and… Learn more →
Lung Cancer
Lung is the most common site of RCC metastasis (20–30% of metastatic RCC patients). Patients… Learn more →
Liver Cancer (Hepatocellular Carcinoma)
Rare metastatic site for RCC. Both may present with elevated LFTs. HCC is typically cirrhosis-related;… Learn more →
Bone Cancer
Bone is a common metastatic site for RCC (15–20% of metastatic disease). RCC bone metastases… Learn more →
Brain Tumors
Brain metastases occur in 5–10% of metastatic RCC patients, often as late events. RCC brain… Learn more →



Supportive Care at HealOnco

Pain Management
Nutrition Support
Counselling
Physiotherapy
Palliative Care
Second Opinion



References

  1. Globocan 2022 – International Agency for Research on Cancer (IARC). Global Cancer Incidence Estimates for Kidney Cancer. gco.iarc.fr
  2. National Center for Biotechnology Information (NCBI). Renal Cell Carcinoma. In: StatPearls. Updated 2024. www.ncbi.nlm.nih.gov
  3. Bhatt JR, Finelli A. Epidemiology of Renal Cell Carcinoma. Nature Rev Urology. 2014. www.ncbi.nlm.nih.gov
  4. Haas NB, et al. Adjuvant Sunitinib or Sorafenib for High-Risk Renal Cell Carcinoma: The ASSURE Trial. New England Journal of Medicine. 2016. PMID: 27959076 www.ncbi.nlm.nih.gov
  5. Motzer RJ, et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2018. PMID: 29443966 www.ncbi.nlm.nih.gov
  6. Powles T, et al. Lenvatinib plus Pembrolizumab in Advanced Renal Cell Carcinoma. New England Journal of Medicine. 2021. PMID: 34349088 www.ncbi.nlm.nih.gov
  7. European Association of Urology (EAU). Renal Cell Carcinoma Guidelines. 2023 Edition. uroweb.org
  8. National Comprehensive Cancer Network (NCCN). Kidney Cancer Guidelines. Version 2024. www.nccn.org
  9. Rini BI, et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine. 2019. PMID: 31092901 www.ncbi.nlm.nih.gov
  10. Choueiri TK, et al. Cabozantinib vs. Sunitinib as Initial Therapy for Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk (METEOR): A Randomized Phase 3 Trial. Journal of Clinical Oncology. 2018. PMID: 28586280 www.ncbi.nlm.nih.gov
  11. Campbell SC, et al. Nephrectomy for Renal Cancer. American Urological Association Guidelines. 2024. www.auanet.org



Medical Disclaimer: This page is for informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified oncologist before making treatment decisions. The cost figures are indicative ranges and may vary by hospital, city, and individual case. HealOnco does not guarantee specific outcomes. Survival statistics are population averages from published sources and do not predict any individual patient’s outcome.

Need help with treatment?Free consultation with oncologist

Book Now